More recently, in close proximity to the end of our study in 2019, the new European League against Rheumatism (EULAR) recommendations for management of APS were published, in which intensifying therapy for patients with recurrent events and potentially for those presenting with arterial thrombosis and/or a high-risk aPL profile was also suggested (4). This evidence concerns the gene FASLG and Arterial thrombosis.